Medication Detail

	(888) 347-3416

Infertility \| Hepatitis \| HIV \| RSV \| Pharmacy \| Shop \| Contact Us

Medication: Leuprolide 2.8mL MDV
Generic Name: Product is generic form of Lupron® 2.8mL MDV
Manufacturer: Various

Indication

Administration

Side Effects

Precautions

Storage

Leuprolide acetate is a GNRH agonist indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. Used as an alternative therapy in Assisted Reproductive Technology to allow clinicians to control the ovulation process. Also used in the treatment of endometriosis. Administered as a single subcutaneous injection using a 3ml 26G 5/8-inch needled syringe. It is supplied as a multidose vial already in solution. Administration will require the use of supplies contained in the Induction / ART Kit. Side effects include hot flashes, bone pain occurring during the first few weeks of treatment, difficulty urinating, and irritation at the injection site. Some individuals may also experience new onset or aggravation of nerve symptoms Response to the medication will be monitored by blood work. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed during the first few weeks of therapy. Leuprolide acetate should be stored at room temperature and protected from light.

<-- Previous Page

Indication	Administration	Side Effects	Precautions	Storage
Leuprolide acetate is a GNRH agonist indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. Used as an alternative therapy in Assisted Reproductive Technology to allow clinicians to control the ovulation process. Also used in the treatment of endometriosis.	Administered as a single subcutaneous injection using a 3ml 26G 5/8-inch needled syringe. It is supplied as a multidose vial already in solution. Administration will require the use of supplies contained in the Induction / ART Kit.	Side effects include hot flashes, bone pain occurring during the first few weeks of treatment, difficulty urinating, and irritation at the injection site. Some individuals may also experience new onset or aggravation of nerve symptoms	Response to the medication will be monitored by blood work. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed during the first few weeks of therapy.	Leuprolide acetate should be stored at room temperature and protected from light.